Strategic partnerships ADL positions itself as a global leader in phage-display reagents and emerging yeast-display solutions, presenting a compelling opportunity to partner on antibody discovery projects for therapeutic and diagnostic research.

End-to-end services With capabilities spanning library construction, screening, expression, and characterization, ADL can be a one-stop supplier for customers seeking streamlined workflows and reduced vendor management.

Proprietary libraries ADL’s ALTHEA Gold, Super Naive OPAL, and MIM libraries offer differentiating capabilities that can attract customers aiming for faster hit discovery and diverse antibody, single-domain antibody, and peptide binder generation.

Emerging display tech Growing emphasis on yeast-display alongside mature phage-display offerings opens upsell potential with customers exploring alternative display platforms for improved affinity maturation and screening efficiency.

Revenue upside With a revenue range of one to ten million and a focused niche in biotech R&D, there is room to expand through targeted outreach to mid-market research labs and biotech firms seeking specialized discovery services and rapid prototyping capabilities.